Securities Code: 4506


Supplementary Financial Data
for the Second Quarter of the Year Ending March 31, 2010
I.
Consolidated
Financial
Highlights

1
II.
Consolidated
Statements
of
Income

3
III.
Consolidated
Balance
Sheets

6
IV. Consolidated Statements of Cash Flows
8
V. Group-to-Parent Ratios, Consolidated Subsidiaries, Numbers of Employees and MRs
9
VI.Quarterly
Business
Results
9
VII.Shareholder Positioning 10
VIII.
Acquisition of Sepracor Inc.
11

IX. Development Pipeline
12
X. Profile of Major Products under Development
15
October 29, 2009

Dainippon Sumitomo Pharma Co., Ltd.
- This document contains forward-looking statements based on management’s assumptions and beliefs in

light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.
- Forecasts for the year ending March 31, 2010 do not include figures of Sepracor Inc.. - All values are rounded. Therefore totals may not be consistent with aggregated figures.

-supplementary1-
I. Consolidated Financial Highlights

1. Highlights of the Statements of Income
(Billions of Yen)
Change (%)
Change (%)
Change (%)
Net sales
134.4
132.2
(1.6)
264.0
0.0
264.0
－
Cost of sales
52.8
51.3
(2.9)
103.7
4.4
105.0
1.2
SG&A expenses
63.3
62.0
(2.2)
129.1
3.5
130.0
0.7
SG&A expenses lessR&D costs
38.5
37.7
(2.1)
76.3
(1.6)
77.0
0.9
R&D costs
24.8
24.2
(2.2)
52.8
11.7
53.0
0.3
Operating income
18.2
18.9
4.1
31.2
(21.7)
29.0
(7.0)
Ordinary income
18.2
19.1
4.6
31.4
(16.6)
27.0
(14.0)
Net income
10.9
12.7
16.4
20.0
(21.9)
18.0
(9.9)
Notes: Cost of sales includes provision for (reversal of) reserve for sales returns.
Earnings per share (yen)
27.35
31.85
50.30
45.30
Return on equity (ROE)
3.4%
3.8%
6.2%
5.5%
32.9%
28.3%
35.8%
39.7%
2. Highlights of the Balance Sheets
(Billions of Yen)
Total assets
391.3
394.2
2.9
Net assets
324.5
333.2
8.7
　
Shareholders' equity
324.4
333.1
8.7
Shareholders' equity ratio
82.9%
84.5%
As of
3/31/09
(A)
As of
9/30/09
(B)
(B) - (A)
"Change(%)" represent ratio of changes from the corresponding period of the previous year. Sumitomo Pharmaceuticals (Suzhou) Co.,Ltd. is newly added as a consolidated subsidiary from this fiscal year.
Payout ratio
Year ending 3/31/10
(Forecasts)
SIx months ended
9/30/09
Six months
ended
9/30/08
Year ended 3/31/09

3. Capital Expenditures and Depreciation
(Billions of Yen)
6.9
2.6
(4.3)
10.6
11.0
0.4
Depreciation and amortization
5.1
5.1
(0.0)
10.7
11.5
0.8
Year ending
3/31/10
(Forecasts)
Change
Capital expenditures(including intangible assets)
Six months
ended
9/30/08
(A)
Six months
ended
9/30/09
(B)
(B) - (A)
Year ended
3/31/09

- Major capital expenditure projects for the year ending March 31, 2010
Integration of product formulations development functions in Technology Research & Development Division :

¥0.90 billion (total budget: ¥0.90 billion, to be completed in January 2010)

-supplementary2-
4. Highlights of the Statements of Cash Flows
(Billions of Yen)
Net cash provided by operating activities
10.4
13.0
2.6
Net cash used in investing activities
(13.0)
2.1
15.1
Net cash used in financing activities
(8.2)
(3.7)
4.6
－
0.5
0.5
45.5
61.4
15.9
Cash and cash equivalents at the endof period
Six
months
ended
9/30/08
（A）
Six
months
ended
9/30/09
（B）
(B)-(A)
Increase related to change in scope ofconsolidation

-supplementary3-

II. Consolidated Statements of Income


1. Statements of Income
(Billions of Yen)
(B)-(A)
Change
(%)
Net sales
134.4
132.2
(2.1)
(1.6)
Overseas sales
12.6
12.4
(0.2)
(1.7)
Cost of sales
52.8
51.3
(1.5)
(2.9)
Gross profit
81.5
80.9
(0.6)
(0.8)
SG&A expenses
63.3
62.0
(1.4)
(2.2)
Labor costs
15.9
16.8
0.8
5.3
Advertising andpromotion costs
2.8
2.1
(0.7)
(25.5)
Sales promotion costs
5.5
5.4
(0.1)
(1.5)
Other costs
14.3
13.4
(0.9)
(6.1)
SG&A expenses less R&Dcosts
38.5
37.7
(0.8)
(2.1)
R&D costs
24.8
24.2
(0.5)
(2.2)
Operating income
18.2
18.9
0.7
4.1
Non-operating income
1.4
1.4
(0.0)
Non-operating expenses
1.4
1.3
(0.1)
Ordinary income
18.2
19.1
0.8
4.6
18.2
19.1
0.8
4.6
Income taxes
7.3
6.4
(0.9)
Minority interests in net income
0.0
0.0
(0.0)
Net income
10.9
12.7
1.8
16.4
Note: Cost of sales includes provision for (reversal of) reserve for sales returns.
Six months
ended
9/30/08
(A)
Six months
ended
9/30/09
(B)
Income before income taxesand minority interests
(Positives)・
Increased sales of
GASMOTIN
®
, PRORENAL
®
,
MEROPEN
®
・
Sales growth of
LONASEN
®
, AmBisome
®
(Negatives)・
Decreased sales of
AMLODIN
®
due to the
influence of generics
・
Cost of sales ratio
39.3%→38.8%
・
Efficient spending of R&D
costs・
Increase in overseas
development cost oflurasidone
・
Decrease in costs related
to new products (AVAPRO
®
／
LONASEN
®
)
・Decrease in TVcommercials, etc.
・
Decrease by expansion of
R&D tax reduction
2. Segment Information
(Billions of Yen)
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Pharma
ceuticals
Other
products
Total
Net sales
106.1
28.2
134.4
103.5
28.7
132.2
206.8
57.2
264.0
205.2
58.8 264.0
17.5
0.7
18.2
17.7
1.2
18.9
29.8
1.3
31.2
Operatingincome
Six months ended
9/30/08
Six months ended
9/30/09
Year ending 3/31/10
（
Forecasts）
Year ended 3/31/09

-supplementary4-

3. Sales of Major Products

Pharmaceuticals（Domestic） （Billions of Yen）
Brand name (Generic name)
Therapeutic indication
Six months
ended
9/30/08
(A)
Six months
ended

9/30 /09
(B)

Change
(%)
(Ｂ)
/
(Ｃ)
(%)
Year ended
3/31/09
Year ending
3/31/10
(Forecasts)
(C)
AMLODIN
®
(amlodipine)
Therapeutic agent for hypertension and angina pectoris

30.5
26.9

(12.0)
54.3
57.9 [48.0]
49.5
GASMOTIN
®
(mosapride citrate)
Gastroprokinetic

9.9
10.4

4.9
49.4
20.2 21.0
PRORENAL
®
(limaprost alfadex)
Vasodilator

7.3
7.8
7.0 50.6
14.8 15.5
MEROPEN
®
(meropenem)
Carbapenem antibiotic
7.3
7.6
4.8
54.9
14.8 [12.9]
13.9
EBASTEL
®
(ebastine)
Long-acting Antiallergic

3.9
4.0
2.6 44.2
10.6
[8.6] 9.1
SUMIFERON
®

(interferon-α NAMALWA))
Natural alpha interferon

3.0
3.0
(0.7)
50.2
6.0
6.0
LONASEN
®
(blonanserin)
Antipsychotic agent
1.3
3.0
122.3 45.6
3.4
6.5
GROWJECT
®
(somatropin)
Growth hormone

2.2
2.4
8.5 51.4
4.3
4.6
MELBIN
®
(metformin)
Oral hypoglycemic

1.6
1.9
17.2 49.1
3.4
3.9
AmBisome
®
(amphotericin B)
Therapeutic agent for systemic fungal infection

1.4
1.9
34.2 43.8
3.1
4.3
DOPS
®
(droxidopa)
Noradrenaline-activating neural function ameliorant

1.9
1.9
(3.0)
51.7 3.8
3.6
EXCEGRAN
®
(zonisamide)
Antiepileptic
1.8
1.8
1.2 48.3
3.6
3.8
GLIMICRON
®
(gliclazide)
Oral hypoglycemic

1.8
1.7
(7.2)
50.2 3.6
3.4
ALMARL
®
(arotinolol)
Therapeutic agent for hypertension, angina pectoris and arrhythmia

1.5
1.5
(5.6)
50.5 3.0
2.9
QVAR
TM
(beclomethasone
dipropionate) Inhaled steroid antiasthmatic
1.8
1.4
(21.5)
46.4 3.6
3.0
LULLAN
®
(perospirone)
Antipsychotic
1.5
1.3
(8.9)
49.8 2.8
2.7
SEDIEL
®
(tandospirone)
Serotonin-agonist antianxiety drug
1.4
1.3
(6.1)
51.2 2.7
2.6
TAGAMET
®
(cimetidine)
H
2
-receptor antagonist
1.4
1.2
(12.0)
51.9 2.7
2.4
AVAPRO
®
(irbesartan)
Therapeutic agent for hypertension

1.3
1.0
(22.2)
25.8

1.5
[6.0] 4.0
TRERIEF
®
(zonisamide)
Therapeutic agent for Parkinson’s disease
－
0.4
－
33.6

－
1.1
(C): Figures in parentheses [ ] are forecasts released on May 11, 2009.